UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 9, 2006
PROXYMED, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Florida
|
|
000-22052
|
|
65-0202059 |
(State or other
jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer
Identification No.) |
1854 Shackleford Court, Suite 200,
Norcross, Georgia 30093-2924
(Address of principal executive offices)
(770) 806-9918
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition
On May 9, 2006, ProxyMed, Inc. d/b/a MedAvant Healthcare Solutions (the “Company”) announced
its financial results for its first quarter ended March 31, 2006. The full text of the press
release issued in connection with the announcement is attached as Exhibit 99.1 to this Current
Report on Form 8-K. Additionally, on May 10, 2006, the Company will hold a teleconference call to
report its financial and operating results for the quarter ended March 31, 2006.
FORWARD LOOKING STATEMENTS — Statements in this release that are “forward-looking statements” are
based on current expectations and assumptions that are subject to risks and uncertainties. In some
cases, forward-looking statements can be identified by terminology such as “may,” “should,”
“potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and
similar expressions. Actual results could differ materially from projected results because of
factors such as: the soundness of our business strategies relative to the perceived market
opportunities; MedAvant’s ability to successfully develop, market, sell, cross-sell, install and
upgrade its clinical and financial transaction services and applications to current and new
physicians, payers, medical laboratories and pharmacies; the ability to compete effectively on
price and support services; MedAvant’s ability and that of its business associates to perform
satisfactorily under the terms of its contractual obligations, and to comply with various
government rules regarding healthcare and patient privacy; entry into markets with vigorous
competition, market acceptance of existing products and services, changes in licensing programs,
product price discounts, delays in product development and related product release schedules, any
of which may cause revenues and income to fall short of anticipated levels; the availability of
competitive products or services; the continued ability to protect the company’s intellectual
property rights, implementation of operating cost structures that align with revenue growth;
uninsured losses; adverse results in legal disputes resulting in liabilities; unanticipated tax
liabilities; the effects of a natural disaster or other catastrophic event beyond our control that
results in the destruction or disruption of any of our critical business or information technology
systems. Any of these factors could cause the actual results to differ materially from the guidance
given at this time. For further cautions about the risks of investing in MedAvant, we refer you to
the documents MedAvant files from time to time with the Securities and Exchange Commission,
including, without limitation, its most recently filed Annual Report on Form 10-K/A.
MedAvant does not assume, and expressly disclaims, any obligation to update information contained
in this document. Although this release may remain available on our website or elsewhere, its
continued availability does not indicate that we are reaffirming or confirming any of the
information contained herein.
###